Vanguard Group Inc. Raises Position in Delcath Systems, Inc. $DCTH

Vanguard Group Inc. lifted its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 13.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,394,028 shares of the company’s stock after buying an additional 169,260 shares during the period. Vanguard Group Inc. owned approximately 4.17% of Delcath Systems worth $17,746,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Quarry LP purchased a new position in Delcath Systems in the fourth quarter valued at about $34,000. Inlight Wealth Management LLC purchased a new position in Delcath Systems in the first quarter valued at about $85,000. NBC Securities Inc. boosted its holdings in Delcath Systems by 99,900.0% in the first quarter. NBC Securities Inc. now owns 10,000 shares of the company’s stock valued at $127,000 after purchasing an additional 9,990 shares during the last quarter. Graham Capital Management L.P. purchased a new position in Delcath Systems in the fourth quarter valued at about $123,000. Finally, PharVision Advisers LLC purchased a new position in Delcath Systems in the fourth quarter valued at about $129,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Price Performance

DCTH opened at $11.02 on Friday. Delcath Systems, Inc. has a 12 month low of $8.08 and a 12 month high of $18.23. The stock has a market cap of $385.48 million, a P/E ratio of 220.40 and a beta of 0.82. The stock’s 50 day moving average price is $11.52 and its 200 day moving average price is $13.07.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. The company had revenue of $24.16 million for the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%. Equities analysts anticipate that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DCTH. HC Wainwright increased their price target on Delcath Systems from $29.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Stephens reaffirmed an “overweight” rating and set a $25.00 target price on shares of Delcath Systems in a report on Monday, June 23rd. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $24.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.